The linker is directly conjugated to a chemotherapeutic agent and when injected into the bloodstream binds to circulating albumin
In the majority of cases, the disorder is detected by electrophoretic screening of plasma proteins, which shows either the complete absence of or the presence of very low amounts of circulating albumin
(1) ranging from 0.
Researchers found that INNO-206, a form of doxorubicin that attaches to circulating albumin
and becomes activated once located at the tumor site, is much better tolerated in animal models than doxorubicin alone, a commonly prescribed chemotherapeutic agent.
Exposure to ischemic myocardium modifies circulating albumin
at its NHZ terminus by different mechanisms, and this modification is the basis of IMA measurement by the albumin cobalt binding (ACB) test (3).
Once administered, INNO-206 binds circulating albumin
via an acid sensitive linker.